AR062775A1 - Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento - Google Patents
Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamentoInfo
- Publication number
- AR062775A1 AR062775A1 ARP070104049A ARP070104049A AR062775A1 AR 062775 A1 AR062775 A1 AR 062775A1 AR P070104049 A ARP070104049 A AR P070104049A AR P070104049 A ARP070104049 A AR P070104049A AR 062775 A1 AR062775 A1 AR 062775A1
- Authority
- AR
- Argentina
- Prior art keywords
- activity
- glp
- polypeptide
- human
- prepare
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 2
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 abstract 1
- 229940123993 Incretin mimetic Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composicion farmacéutica capaz de mejorar la actividad de GLP-1 en un ser humano, que comprende al menos un polipéptido que tiene actividad de GLP-1, en donde dicho polipéptido proporciona una concentracion plasmática máxima de dicho polipéptido de al menos aproximadamente 0,6 nM y un valor de área bajo la curva de dicho polipéptido que es al menos aproximadamente 3,5 nM x día durante el período de una semana cuando es administrado a un ser humano. Uso de dicha composicion para preparar un medicamento util para mejorar la actividad GLP-1. Dicho polipéptido que tiene actividad de GLP-1 comprende al menos un agonista de GLP-1. Al menos un agonista de GLP-1 se selecciona entre el grupo de: hormona incretina y/o fragmento, variante y/o conjugado de la misma, y mimético de incretina y/o fragmento, variante y/o conjugado del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82547206P | 2006-09-13 | 2006-09-13 | |
| US86839106P | 2006-12-04 | 2006-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062775A1 true AR062775A1 (es) | 2008-12-03 |
Family
ID=39184534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104049A AR062775A1 (es) | 2006-09-13 | 2007-09-12 | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8338369B2 (es) |
| EP (1) | EP2073834B1 (es) |
| JP (2) | JP5524620B2 (es) |
| KR (1) | KR101472601B1 (es) |
| CN (1) | CN103705911A (es) |
| AR (1) | AR062775A1 (es) |
| AU (1) | AU2007296499C1 (es) |
| BR (1) | BRPI0716765A8 (es) |
| CA (1) | CA2662622C (es) |
| CL (1) | CL2007002634A1 (es) |
| CR (1) | CR10684A (es) |
| EA (1) | EA017159B1 (es) |
| ES (1) | ES2442869T3 (es) |
| IL (1) | IL197448A (es) |
| JO (1) | JO2945B1 (es) |
| MA (1) | MA30768B1 (es) |
| MX (1) | MX2009002863A (es) |
| MY (1) | MY149911A (es) |
| NO (1) | NO20091266L (es) |
| NZ (1) | NZ575419A (es) |
| PE (2) | PE20080840A1 (es) |
| SG (2) | SG10201501749WA (es) |
| TW (1) | TWI430806B (es) |
| WO (1) | WO2008033888A2 (es) |
| ZA (1) | ZA200901548B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514900A (ja) | 2005-11-04 | 2009-04-09 | スミスクライン・ビーチャム・コーポレイション | 血糖降下剤の投与方法 |
| SMT201700189T1 (it) * | 2008-12-10 | 2017-05-08 | Glaxosmithkline Llc | Composizioni farmaceutiche di albiglutide |
| WO2011140176A1 (en) * | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| CA2832811A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
| AU2014261336B2 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| HUE057361T2 (hu) | 2013-05-28 | 2022-05-28 | Takeda Pharmaceuticals Co | Peptid vegyület |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| TW202423476A (zh) * | 2021-03-23 | 2024-06-16 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| JP2001501593A (ja) * | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 胃腸運動を調節するための方法 |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| EA200100289A1 (ru) * | 1998-08-28 | 2001-10-22 | Эли Лилли Энд Компани | Способ введения инсулинотропных пептидов |
| US6329336B1 (en) * | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| DK1355942T3 (da) * | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US7259233B2 (en) * | 2000-12-13 | 2007-08-21 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| EP1542712A2 (en) * | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| US7101843B2 (en) * | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7238670B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| CA2484556A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BR0306706A (pt) * | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1689757T3 (en) * | 2003-11-12 | 2014-12-08 | Sino Med Internat Alliance Inc | HETEROCYCLIC DRY ACID COMPOUNDS |
| CN100577412C (zh) * | 2004-01-13 | 2010-01-06 | 旭硝子株式会社 | 多层层合体 |
| SI1729795T1 (sl) * | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
| JP2009514900A (ja) * | 2005-11-04 | 2009-04-09 | スミスクライン・ビーチャム・コーポレイション | 血糖降下剤の投与方法 |
| EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
-
2007
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko not_active Expired - Fee Related
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en not_active Ceased
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
-
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
-
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
-
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
| ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
| PE20230819A1 (es) | Composiciones y usos de glp-1 | |
| BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| PE20081804A1 (es) | Polipeptidos del receptor de activina variante y usos de los mismos | |
| ES2250416T3 (es) | Estimulante de secreciohn de hormona de crecimiento. | |
| CY1112082T1 (el) | Υγρη φαρμακοτεχνικη μορφη fsh | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| AR063782A1 (es) | Parche y metodo transdermico para emesis | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| PT2131810E (pt) | Administração oral de uma calcitonina | |
| SE0402345D0 (sv) | A metered medication dose | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| TW200603787A (en) | Topical preparations containing ambroxol | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| ECSP044979A (es) | Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña | |
| PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
| DK1482919T3 (da) | Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |